Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy
Authors
Keywords
-
Journal
Scientific Reports
Volume 8, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-03-29
DOI
10.1038/s41598-018-23803-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunity to CRISPR Cas9 and Cas12a therapeutics
- (2017) Wei Leong Chew Wiley Interdisciplinary Reviews-Systems Biology and Medicine
- Integrase-Deficient Lentiviral Vector as an All-in-One Platform for Highly Efficient CRISPR/Cas9-Mediated Gene Editing
- (2017) Pavel I. Ortinski et al. Molecular Therapy-Methods & Clinical Development
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Genetic and Epigenetic Regulation of PD-1 Expression
- (2016) Alexander P. R. Bally et al. JOURNAL OF IMMUNOLOGY
- CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles
- (2016) Wei-Jing Dai et al. Molecular Therapy-Nucleic Acids
- Chimeric antigen receptor T-cell therapy for solid tumors
- (2016) Kheng Newick et al. Molecular Therapy-Oncolytics
- CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
- (2016) Shu Su et al. Scientific Reports
- Adenovirus-Mediated Somatic Genome Editing ofPtenby CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses
- (2015) Dan Wang et al. HUMAN GENE THERAPY
- Lentiviral vectors in cancer immunotherapy
- (2015) Robyn AA Oldham et al. Immunotherapy
- Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
- (2015) Lieping Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+T cells
- (2015) Pamela M. Odorizzi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- TNF biology, pathogenic mechanisms and emerging therapeutic strategies
- (2015) George D. Kalliolias et al. Nature Reviews Rheumatology
- Generation of knock-in primary human T cells using Cas9 ribonucleoproteins
- (2015) Kathrin Schumann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- 2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond
- (2015) Paolo A. Ascierto et al. EBioMedicine
- Efficient gene editing in adult mouse livers via adenoviral delivery of CRISPR/Cas9
- (2014) Ranran Cheng et al. FEBS LETTERS
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing
- (2014) Dirk Heckl et al. NATURE BIOTECHNOLOGY
- Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
- (2013) L. B. John et al. CLINICAL CANCER RESEARCH
- Genome engineering using the CRISPR-Cas9 system
- (2013) F Ann Ran et al. Nature Protocols
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lentiviral Vectors for Cancer Immunotherapy and Clinical Applications
- (2013) Therese Liechtenstein et al. Cancers
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
- (2011) Lukas Baitsch et al. JOURNAL OF CLINICAL INVESTIGATION
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now